DRUG vs. NXL

Last updated Aug 1, 2026

DRUG (Bright Minds Biosciences Inc) and NXL (Nexalin Technology Inc.) are both stocks. Both are in the Healthcare sector — DRUG in Biotechnology, NXL in Medical Devices. Over the past 3 years, DRUG returned 165.15%/yr vs -23.09%/yr for NXL. Their 0.06 correlation means their historical movements had little consistent relationship.

Performance

DRUG vs. NXL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bright Minds Biosciences Inc (DRUG) and Nexalin Technology Inc. (NXL). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, DRUG achieves a -6.13% return, which is significantly higher than NXL's -39.46% return.

DRUG

• 1D: -1.84%
• 1M: 8.37%
• 6M: -5.77%
• YTD: -6.13%
• 1Y: 117.84%
• 3Y*: 165.15%
• 5Y*: 25.53%
• 10Y*: —
• ALL TIME*: 21.18%

NXL

• 1D: -1.23%
• 1M: -6.43%
• 6M: -40.74%
• YTD: -39.46%
• 1Y: -65.84%
• 3Y*: -23.09%
• 5Y*: —
• 10Y*: —
• ALL TIME*: -41.54%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
DRUG Bright Minds Biosciences Inc	$15.79M	$18.06M	$22.80M
NXL Nexalin Technology Inc.	$93.23K	$114.40K	$252.28K

DRUG vs. NXL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
DRUG Bright Minds Biosciences Inc	-6.13%	116.66%	2,418.88%	-61.35%	-42.19%
NXL Nexalin Technology Inc.	-39.46%	-79.78%	581.82%	-45.95%	-72.26%

Correlation

The correlation between DRUG and NXL is 0.06, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.06
Correlation (3Y) Balances recent behavior with more history.	0.08
Correlation (All Time) Calculated using the full available price history since Sep 16, 2022	0.06

Fundamentals

Market Cap DRUG : $717.01M NXL : $7.44M
EPS DRUG : -CA$3.37 NXL : -$0.44
PB Ratio DRUG : 3.19 NXL : 2.32
Total Revenue (TTM) DRUG : CA$0.00 NXL : $275.58K
Gross Profit (TTM) DRUG : -CA$20.13K NXL : -$950.31K
EBITDA (TTM) DRUG : -CA$31.36M NXL : -$8.37M

Return for Risk

DRUG vs. NXL — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

DRUG

DRUG Risk / Return Rank: 85
DRUG Sharpe Ratio Rank: 87
DRUG Sortino Ratio Rank: 86
DRUG Omega Ratio Rank: 82
DRUG Calmar Ratio Rank: 87
DRUG Martin Ratio Rank: 85

NXL

NXL Risk / Return Rank: 22
NXL Sharpe Ratio Rank: 24
NXL Sortino Ratio Rank: 27
NXL Omega Ratio Rank: 28
NXL Calmar Ratio Rank: 13
NXL Martin Ratio Rank: 20

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

DRUG vs. NXL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bright Minds Biosciences Inc (DRUG) and Nexalin Technology Inc. (NXL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	DRUG	NXL	Difference
Sharpe ratio: Return per unit of total volatility	1.66	-0.44	+2.10
Sortino ratio: Return per unit of downside risk	2.45	-0.23	+2.68
Omega ratio: Gain probability vs. loss probability	1.28	0.98	+0.30
Calmar ratio: Return relative to maximum drawdown	3.07	-0.80	+3.87
Martin ratio: Return relative to average drawdown	6.98	-1.08	+8.06

DRUG vs. NXL - Sharpe Ratio Comparison

The current DRUG Sharpe Ratio is 1.66, which is higher than the NXL Sharpe Ratio of -0.44. The chart below compares the historical Sharpe Ratios of DRUG and NXL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

DRUG vs. NXL - Drawdown Comparison

The maximum DRUG drawdown since its inception was -97.68%, which is greater than NXL's maximum drawdown of -92.64%. Use the drawdown chart below to compare losses from any high point for DRUG and NXL.

Drawdown Indicators

	DRUG	NXL	Difference
Max Drawdown Largest peak-to-trough decline	-97.68%	-92.64%	-5.04%
Max Drawdown (1Y) Largest decline over 1 year	-38.35%	-82.74%	+44.39%
Max Drawdown (3Y) Largest decline over 3 years	-76.98%	-92.64%	+15.66%
Max Drawdown (5Y) Largest decline over 5 years	-97.68%	—	—
Current Drawdown Current decline from peak	-23.68%	-92.25%	+68.57%
Average Drawdown Average peak-to-trough decline	-58.07%	-67.08%	+9.01%
Ulcer Index Depth and duration of drawdowns from previous peaks	16.82%	61.18%	-44.36%

Volatility

DRUG vs. NXL - Volatility Comparison

The current volatility for Bright Minds Biosciences Inc (DRUG) is 18.09%, while Nexalin Technology Inc. (NXL) has a volatility of 42.51%. This indicates that DRUG experiences smaller price fluctuations and is considered to be less risky than NXL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DRUG	NXL	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.09%	42.51%	-24.42%
Volatility (6M) Calculated over the trailing 6-month period	41.04%	79.76%	-38.72%
Volatility (1Y) Calculated over the trailing 1-year period	70.90%	149.77%	-78.87%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	662.78%	164.60%	+498.18%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	639.92%	164.60%	+475.32%

Dividends

DRUG vs. NXL - Dividend Comparison

Neither DRUG nor NXL has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both DRUG and NXL in my portfolio?

DRUG and NXL have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, DRUG or NXL?

NXL has higher volatility (42.51%) compared to DRUG (18.09%). In terms of maximum drawdown, DRUG dropped -97.68% vs NXL's -92.64%.

Which has better risk-adjusted returns?

DRUG currently has the higher Sharpe Ratio (1.66 vs -0.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.